查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年神經調節市場預測：按類型、生物材料、技術、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383435

2030 年神經調節市場預測：按類型、生物材料、技術、應用、最終用戶和地區進行的全球分析

Neuromodulation Market Forecasts to 2030 - Global Analysis By Type, Biomaterial, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球神經調節市場規模將達到 68 億美元，預計 2030 年將達到 168 億美元，預測期內年複合成長率為 13.8%。

神經調節是一種醫療程序，涉及向神經系統特定區域提供電或化學刺激的植入設備。它用於治療各種神經和精神疾病。許多神經調節方法是非侵入性或微創的，這意味著它們不涉及手術或主要的物理干涉。這可以加快康復速度並降低與侵入性手術相關的風險。

根據美國疾病管制與預防美國(CDC) 的數據，中風是美國的首要死因，2019 年有 15 萬美國死亡。

擴大神經調節療法的接受度

神經調節治療方法擴大被用作手術和鴉片類藥物等傳統醫學治療的安全有效的替代方案。與傳統治療方法相比，這些治療方法已被證明具有更少的副作用和更低的成癮風險，同時可以長期緩解慢性疼痛等神經病變。此外，廣泛的臨床研究和臨床試驗已經確定了神經調節治療的有效性和安全性。只要神經調節療法被認為是一種安全有效的治療方法，特別是隨著神經系統疾病的盛行率不斷增加，神經調節設備市場就有望擴大。隨著神經調節治療需求的增加，市場預計將擴大。

藥物偏好

在神經系統疾病的治療中，患者往往喜歡藥物治療而不是神經調節治療。這是因為患者不知道可以使用基於神經調節裝置的手術替代方案。在一些國家，外科醫生也表現出這種意識的缺乏。由於缺乏對使用生物材料和神經調節設備治療多種神經系統疾病的好處的認知，預計將在預測期內限制該市場的成長。

技術進步

技術開拓對神經調節領域產生重大影響，為市場擴張和進步提供了巨大潛力。迄今為止的發展導致設備日益複雜和高效，改善了患者的治療效果並擴大了神經調節治療的應用。更緊湊的植入式設備已被開發出來，以提高患者的舒適度並實現侵入性較小的手術。這些進展提高了患者的可接受性，擴大了神經調節治療的範圍，並降低了其侵入性程度。

高成本

這些設備和治療方法的高成本經常被認為是其採用和使用的障礙，因為它會限制患者和提供者的使用。神經調節設備的開發和製造成本高昂，這些成本通常由病人、醫院和保險公司承擔。無力負擔神經調節設備和治療方法的患者可能無法接受它們，尤其是在醫療資源不足的國家。因此，高成本是市場拓展的主要障礙。

COVID-19 的影響

由於許多國家持續封鎖，大多數醫院都關閉，因此預計 COVID-19 大流行將阻礙神經調節市場的擴張。 COVID-19 大流行為公共衛生帶來了嚴峻挑戰。同時，世界各地的許多診所和醫院正在進行結構性改革，以提高醫院容量並提供更好的醫療設施。

預計內部部門在預測期內將是最大的

由於患有心臟相關疾病、憂鬱症和各種頭痛的患者數量不斷增加，預計內科所佔比例最大。神經調節裝置對於慢性疼痛的治療至關重要，因為它們採用非侵入性或微創技術。內部神經調節是一種更有效的治療方法，因為它是一種透過電刺激疼痛部位的特定神經來改變神經活動的裝置。

在預測期內，年複合成長率最高的將是慢性疼痛領域。

預計慢性疼痛細分市場在預測期內將出現良好的成長。慢性疼痛管理有助於透過藥物、治療方法和生活方式改變來緩解疼痛。電刺激設備對疼痛管理有重大影響，因為它們最初設計用於緩解各種型態的急性和慢性疼痛。久坐的生活方式、高齡化和慢性病的流行是導致慢性疼痛的危險因子。因此，慢性疼痛發病率的增加預計將在預測期內推動該細分市場的成長。

比最大的地區

在預測期內，北美佔據最大的市場佔有率。龐大的製藥和生物製藥行業、成熟的市場參與企業以及美國為引進最尖端科技而增加的投資預計將推動該國市場的成長。此外，在過去的年度中，PD 在北美的發生率比多發性硬化症、肌肉萎縮症和盧伽雷氏症的總合還要多。因此，該國的研究人員正在詳細研究神經調節來治療這些神經系統疾病。這為尖端神經調節設備的開發開闢了新途徑，預計將有助於該地區的整體市場成長。

複合年複合成長率最高的地區：

由於患者人數眾多、醫療保健支出不斷增加以及對神經調節療法的認知不斷增強，預計亞太地區在預測期內將實現盈利成長。該地區也投入大量資金用於神經調節療法和設備的研發。由於患者人數眾多且神經調節治療的使用不斷增加，中國和日本目前佔據該地區的前兩名。然而，該地區其他國家的市場也大幅擴張，例如澳洲、韓國、印度和韓國。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球神經調節市場：依類型

  • 介紹
  • 經皮神經電刺激
  • 呼吸電刺激
  • 經顱磁刺激
  • 腦深部刺激
  • 脊髓刺激
  • 薦椎神經刺激
  • 迷走神經刺激
  • 胃電刺激

第6章 全球神經調節市場：依生物材料分類

  • 介紹
  • 金屬生物材料
  • 高分子生物材料
  • 陶瓷生物材料

第7章 全球神經調節市場：依技術分類

  • 介紹
  • 外部的
  • 內部的

第8章 全球神經調節市場：依應用分類

  • 介紹
  • 偏頭痛
  • 帕金森氏症
  • 尿失禁和大便失禁
  • 慢性疼痛
  • 故障恢復症候群
  • 發抖
  • 癲癇
  • 憂鬱症
  • 其他用途

第9章 全球神經調節市場：依最終用戶分類

  • 介紹
  • 診所和物理治療中心
  • 醫院及門診手術中心

第10章 全球神經調節市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Nevro Corporation
  • NeuroSigma
  • Bioventus Inc.
  • Medtronic
  • NeuroPace Inc
  • Neuronetics
  • Boston Scientific Corporation
  • LivaNova PLC
  • MicroTransponder
  • Abbott
  • Synapse Biomedical Inc
  • Nuvectra
  • Soterix Medical
Product Code: SMRC24284

According to Stratistics MRC, the Global Neuromodulation Market is accounted for $6.8 billion in 2023 and is expected to reach $16.8 billion by 2030 growing at a CAGR of 13.8% during the forecast period. Neuromodulation is a medical procedure involving implanted devices to deliver electrical or chemical stimulation to specific areas of the nervous system. It is used to treat a variety of neurological and psychiatric conditions. Numerous neuromodulation methods don't involve surgery or significant physical intervention because they are non-invasive or minimally invasive. This enables quicker recovery times and lowers the risks related to invasive procedures.

According to Centers for Disease Control and Prevention (CDC), stroke is a leading cause of death in the U.S., killing 150,000 Americans in 2019.

Market Dynamics:

Driver:

Rising acceptance of neuromodulation therapies

The use of neuromodulation therapies as secure and efficient substitutes for conventional medical procedures like surgery and opioids is growing. Compared to conventional treatments, these therapies have been demonstrated to have fewer side effects and a lower risk of addiction while providing long-term relief for neurological disorders such as chronic pain. Furthermore, an abundance of clinical research and trials have substantiated the efficacy and safety of neuromodulation treatments. The market for neuromodulation devices is anticipated to rise as long as neuromodulation therapies are acknowledged as safe and effective forms of treatment, particularly in light of the rising incidence of neurological disorders. The market is expected to grow as a result of the growing need for neuromodulation therapies.

Restraint:

Preference of drug therapies

While treating neurological disorders, patients frequently favor drug therapies over neuromodulation. This is because of patients' lack of knowledge regarding the availability of neuromodulation device-based alternative surgical treatments. In certain countries, surgeons also exhibit this lack of awareness. The lack of awareness about the benefits of using biomaterials or neuromodulation devices to treat several neurological disorders is expected to restrain the growth of this market during the forecast period.

Opportunity:

Technological advancements

Technological developments offer enormous potential for market expansion and advancement and have greatly impacted the field of neuromodulation. The development that has been made has led to the creation of increasingly complex and efficient devices, enhanced patient outcomes, and broadened the scope of uses for neuromodulation treatments. Devices that are more compact and implantable have been created, improving patient comfort and enabling less invasive procedures. These developments have improved patient acceptance, broadened the range of applications for neuromodulation therapies, and decreased the degree of invasiveness.

Threat:

High cost

The high cost of these devices and therapies is often cited as a barrier to their adoption and use, as it can limit access for patients and healthcare providers. Neuromodulation devices can be costly to develop and produce, and this expense is frequently borne by patients, hospitals, and insurance companies. Patients who cannot afford neuromodulation devices and therapies may not be able to receive them, particularly in nations with inadequate healthcare resources. Therefore, high cost is a significant barrier for the market expansion.

COVID-19 Impact

The COVID-19 pandemic is expected to hinder the neuromodulation market's expansion since most hospitals are closed as a result of the ongoing lockdowns in many nations. The COVID-19 pandemic has caused a serious problem for public health. On the other hand, a great number of clinics and hospitals around the world underwent structural changes to boost hospital capacity and offer better healthcare facilities.

The internal segment is expected to be the largest during the forecast period

The internal segment is estimated to hold the largest share, due to increase in the number of patients suffering from heart-related diseases, depression, and various headache disorders. Neuromodulation devices are vital in the treatment of chronic pain because they employ non-invasive or minimally invasive technology. Internal neuromodulation is a more effective way to treat the condition because the devices are made to electrically stimulate a specific nerve at the pain site in order to alter nerve activity.

The chronic pain segment is expected to have the highest CAGR during the forecast period

The chronic pain segment is anticipated to have lucrative growth during the forecast period. Chronic pain management helps relieve pain with the use of drugs, therapies, and lifestyle changes. Since electrical stimulation devices were initially designed to relieve various forms of acute and chronic pain, they have a significant impact on pain management. A sedentary lifestyle, an aging population, and the prevalence of chronic conditions are a few risk factors that could lead to chronic pain. Thus, during the projected period, the growing incidence of chronic pain is anticipated to propel the segment's growth.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The large pharmaceutical and biopharmaceutical industries, along with the presence of well-established market players and growing investments in the United States for the adoption of cutting-edge technologies, are anticipated to drive the market's growth in this country. Furthermore, during the past decade, PD has become more common in North America than multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease combined. Therefore, in order to treat these neurological disorders, the nation's researchers investigate neuromodulation in great detail. This is expected to create new avenues for the development of cutting-edge neuromodulation devices and contribute to the region's overall market growth.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to the large patient population, increasing healthcare expenditure, and rising awareness about neuromodulation therapies. Considerable funds are also being invested in the region's research and development of neuromodulation therapies and devices. Because of their sizable patient populations and rising use of neuromodulation treatments, China and Japan presently hold the top two positions in the region. However, the market is expanding significantly in other nations in the region as well, including Australia, South Korea, India, and South Korea.

Key players in the market

Some of the key players in the Neuromodulation Market include: Nevro Corporation, NeuroSigma, Bioventus Inc., Medtronic, NeuroPace Inc, Neuronetic, Boston, Scientific Corporation, LivaNova PLC, MicroTransponder, Abbott, Synapse Biomedical Inc, Nuvectra and Soterix Medical.

Key Developments:

In February 2022, Medtronic (Ireland) received FDA approval for its InterStim X System, a next-generation personalized sacral nerve stimulation therapy for bladder and bowel control.

In June 2021, NeuroSigma (US) and KT Corporation (South Korea) signed a memorandum of understanding for a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy.

In January 2020, Medtronic Plc (Ireland) acquired Stimgenics, LLC (US), a privately held US-based company. This acquisition helped strengthen Medtronic's portfolio of spinal cord stimulation systems.

Types Covered:

  • Transcutaneous Electrical Nerve Stimulation
  • Respiratory Electrical Stimulation
  • Transcranial Magnetic Stimulation
  • Deep Brain Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Gastric Electrical Stimulation

Biomaterials Covered:

  • Metallic Biomaterial
  • Polymeric Biomaterial
  • Ceramic Biomaterial

Technologies Covered:

  • External
  • Internal

Applications Covered:

  • Migraine
  • Parkinson Disease
  • Urinary And Fecal Incontinence
  • Chronic Pain
  • Failed Back Syndrome
  • Tremor
  • Epilepsy
  • Depression
  • Other Applications

End Users Covered:

  • Clinics & Physiotherapy Centers
  • Hospitals & Ambulatory Surgery Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuromodulation Market, By Type

  • 5.1 Introduction
  • 5.2 Transcutaneous Electrical Nerve Stimulation
  • 5.3 Respiratory Electrical Stimulation
  • 5.4 Transcranial Magnetic Stimulation
  • 5.5 Deep Brain Stimulation
  • 5.6 Spinal Cord Stimulation
  • 5.7 Sacral Nerve Stimulation
  • 5.8 Vagus Nerve Stimulation
  • 5.9 Gastric Electrical Stimulation

6 Global Neuromodulation Market, By Biomaterial

  • 6.1 Introduction
  • 6.2 Metallic Biomaterial
  • 6.3 Polymeric Biomaterial
  • 6.4 Ceramic Biomaterial

7 Global Neuromodulation Market, By Technology

  • 7.1 Introduction
  • 7.2 External
  • 7.3 Internal

8 Global Neuromodulation Market, By Application

  • 8.1 Introduction
  • 8.2 Migraine
  • 8.3 Parkinson Disease
  • 8.4 Urinary And Fecal Incontinence
  • 8.5 Chronic Pain
  • 8.6 Failed Back Syndrome
  • 8.7 Tremor
  • 8.8 Epilepsy
  • 8.9 Depression
  • 8.10 Other Applications

9 Global Neuromodulation Market, By End User

  • 9.1 Introduction
  • 9.2 Clinics & Physiotherapy Centers
  • 9.3 Hospitals & Ambulatory Surgery Centers

10 Global Neuromodulation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Nevro Corporation
  • 12.2 NeuroSigma
  • 12.3 Bioventus Inc.
  • 12.4 Medtronic
  • 12.5 NeuroPace Inc
  • 12.6 Neuronetics
  • 12.7 Boston Scientific Corporation
  • 12.8 LivaNova PLC
  • 12.9 MicroTransponder
  • 12.10 Abbott
  • 12.11 Synapse Biomedical Inc
  • 12.12 Nuvectra
  • 12.13 Soterix Medical

List of Tables

  • Table 1 Global Neuromodulation Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neuromodulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Neuromodulation Market Outlook, By Transcutaneous Electrical Nerve Stimulation (2021-2030) ($MN)
  • Table 4 Global Neuromodulation Market Outlook, By Respiratory Electrical Stimulation (2021-2030) ($MN)
  • Table 5 Global Neuromodulation Market Outlook, By Transcranial Magnetic Stimulation (2021-2030) ($MN)
  • Table 6 Global Neuromodulation Market Outlook, By Deep Brain Stimulation (2021-2030) ($MN)
  • Table 7 Global Neuromodulation Market Outlook, By Spinal Cord Stimulation (2021-2030) ($MN)
  • Table 8 Global Neuromodulation Market Outlook, By Sacral Nerve Stimulation (2021-2030) ($MN)
  • Table 9 Global Neuromodulation Market Outlook, By Vagus Nerve Stimulation (2021-2030) ($MN)
  • Table 10 Global Neuromodulation Market Outlook, By Gastric Electrical Stimulation (2021-2030) ($MN)
  • Table 11 Global Neuromodulation Market Outlook, By Biomaterial (2021-2030) ($MN)
  • Table 12 Global Neuromodulation Market Outlook, By Metallic Biomaterial (2021-2030) ($MN)
  • Table 13 Global Neuromodulation Market Outlook, By Polymeric Biomaterial (2021-2030) ($MN)
  • Table 14 Global Neuromodulation Market Outlook, By Ceramic Biomaterial (2021-2030) ($MN)
  • Table 15 Global Neuromodulation Market Outlook, By Technology (2021-2030) ($MN)
  • Table 16 Global Neuromodulation Market Outlook, By External (2021-2030) ($MN)
  • Table 17 Global Neuromodulation Market Outlook, By Internal (2021-2030) ($MN)
  • Table 18 Global Neuromodulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global Neuromodulation Market Outlook, By Migraine (2021-2030) ($MN)
  • Table 20 Global Neuromodulation Market Outlook, By Parkinson Disease (2021-2030) ($MN)
  • Table 21 Global Neuromodulation Market Outlook, By Urinary And Fecal Incontinence (2021-2030) ($MN)
  • Table 22 Global Neuromodulation Market Outlook, By Chronic Pain (2021-2030) ($MN)
  • Table 23 Global Neuromodulation Market Outlook, By Failed Back Syndrome (2021-2030) ($MN)
  • Table 24 Global Neuromodulation Market Outlook, By Tremor (2021-2030) ($MN)
  • Table 25 Global Neuromodulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 26 Global Neuromodulation Market Outlook, By Depression (2021-2030) ($MN)
  • Table 27 Global Neuromodulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global Neuromodulation Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Neuromodulation Market Outlook, By Clinics & Physiotherapy Centers (2021-2030) ($MN)
  • Table 30 Global Neuromodulation Market Outlook, By Hospitals & Ambulatory Surgery Centers (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.